The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Generating Stronger And Smarter T Cells For Cancer Therapy
Funder
National Health and Medical Research Council
Funding Amount
$310,332.00
Summary
White blood cells from cancer patients can be modified in the laboratory to react against tumours. These cells can then be given back to the patient, which can sometimes cause cancer regression. However, often the white blood cells lack strength, or they lack the ability to distinguish between tumour and normal tissues of the body. In this project we seek to make stronger and smarter white blood cells that can deliver a lethal hit against tumours without damaging essential organs of the body.
Investigation Of Regulators That Control The Pro-survival Molecule MCL1 And Its Stabililty In Lymphoma And Myeloma Cells
Funder
National Health and Medical Research Council
Funding Amount
$169,162.00
Summary
B cell malignancies are common and in many cases result in mortality. The BCL-2 family protein MCL-1 has been shown to be over-expressed in many B cell malignancies. However, the regulation and biology of MCL-1 in these cancers remains largely unknown. We aim to define mechanisms that control regulation of MCL-1 expression in cancer cells at the transcriptional and protein level and hence identify new therapeutic targets.
The Role Of The Transcription Factor Blimp-1 In Tumour Immunity
Funder
National Health and Medical Research Council
Funding Amount
$642,674.00
Summary
Regulatory T (Treg) cells function by suppressing immune system activity, ensuring that our immune system does not mount a response against our own tissue. In cancer, Treg cells suppress anti-tumour immunity, facilitating tumour growth. Recently we have identified a group of active Treg cells that may be the key drivers of immune response regulation. Our work will examine the role of these active Treg cells in tumour immunity, opening the door to more effective targeting of Treg cells in cancer.
microRNAs and the control of T lymphocyte differentiation, function and malignant transformation. The molecular mechanism of the immune system is not completely understood. This project will investigate how transcription factors and microRNAs, two major types of regulatory molecules work together to control immune responses. The results from this research will assist in the design of better vaccination strategies and treat certain lymphomas.
My goal is to boost the immune system against cancer to develop new therapies. I aim to do this by genetically engineering the immune system and using drugs to help strengthen white blood cells of the immune system. Tumors can actively fight immunity by producing suppressive molecules. I am seeking to identify and understand these molecules in order to block them and help the immune system fight cancer. Using this knowledge, I aim to start new clinical trials for cancer.
Discovery Early Career Researcher Award - Grant ID: DE180100484
Funder
Australian Research Council
Funding Amount
$365,058.00
Summary
Tipping the balance from tolerance to immunity for the devil facial tumour. This project aims to develop a single-shot vaccine for the Tasmanian devil facial tumour disease. The disease is an enigma because the transmissible tumours are simultaneously cancer, infections, and genetically mismatched tissue grafts. This project will focus on immune molecules that are revolutionising human oncology, and will develop techniques to understand and systematically test the function of these key molecules ....Tipping the balance from tolerance to immunity for the devil facial tumour. This project aims to develop a single-shot vaccine for the Tasmanian devil facial tumour disease. The disease is an enigma because the transmissible tumours are simultaneously cancer, infections, and genetically mismatched tissue grafts. This project will focus on immune molecules that are revolutionising human oncology, and will develop techniques to understand and systematically test the function of these key molecules in Tasmanian devils. Understanding the role of these immune molecules will accelerate development of a vaccine to help save the devil and has the potential to shed light on general principles relating to how the immune system balances tolerance and immunity.Read moreRead less
Immunisation to protect against transmissible cancers in Tasmanian devils. This project aims to identify the immune escape mechanisms that the transmissible cancers, Devil Facial Tumour Disease (DFTD) use to avoid being killed by the immune system. Since the discovery of the second transmissible cancer (DFT2) mystery surrounds whether the devils immune system can respond to this cancer, hence this project will investigate the immune response to DFT2. The final aims are to develop a vaccine with ....Immunisation to protect against transmissible cancers in Tasmanian devils. This project aims to identify the immune escape mechanisms that the transmissible cancers, Devil Facial Tumour Disease (DFTD) use to avoid being killed by the immune system. Since the discovery of the second transmissible cancer (DFT2) mystery surrounds whether the devils immune system can respond to this cancer, hence this project will investigate the immune response to DFT2. The final aims are to develop a vaccine with the potential to protect healthy devils and cure devils with DFTD.Read moreRead less
The Role Of Interleukin (IL)-27 In The Endogenous Anti-tumour Immune Response And The Use Of An IL-27 Agonist As A Cancer Therapeutic.
Funder
National Health and Medical Research Council
Funding Amount
$473,960.00
Summary
Our data in mice suggest that immune cell signalling protein, interleukin (IL)-27, enhances anti-tumour immune responses and slows growth of mammary tumours and carcinogen induced sarcomas. This project aims to test how IL-27 promotes protective anti-tumour immune responses and to develop a modified IL-27 protein that will be tested as a cancer therapeutic in mice. This will be the first study to examine IL-27 function using physiological tumour models and may provide proof of concept for a new ....Our data in mice suggest that immune cell signalling protein, interleukin (IL)-27, enhances anti-tumour immune responses and slows growth of mammary tumours and carcinogen induced sarcomas. This project aims to test how IL-27 promotes protective anti-tumour immune responses and to develop a modified IL-27 protein that will be tested as a cancer therapeutic in mice. This will be the first study to examine IL-27 function using physiological tumour models and may provide proof of concept for a new therapeutic strategy for some human cancers.Read moreRead less
Regulation And Mechanisms Of Cytotoxic Lymphocyte Function
Funder
National Health and Medical Research Council
Funding Amount
$631,010.00
Summary
The immune system is the essential complex barrier that protects the organism for infections and some malignancies. Despite considerable efforts, the mechanism by which immune cells kill dangerous unwanted cells is poorly understood. This project will investigate the mechanism of action and the role in human pathologies of a key component of the immune system, a toxic protein perforin.